The global Parkinson’s disease biomarkers market is witnessing substantial growth due to increasing prevalence of neurodegenerative disorders, rising demand for early diagnosis, advancements in precision medicine, and innovations in biomarker-based testing technologies. Companies operating in this market are heavily investing in neurodiagnostics, AI-powered biomarker discovery, imaging solutions, and molecular testing platforms to strengthen their market position. Below is a detailed analysis of major companies shaping the Parkinson’s disease biomarkers industry.
Parkinson’s Disease Biomarkers Market Company Details
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. is headquartered in Basel, Switzerland, and is one of the leading global healthcare companies specializing in pharmaceuticals and diagnostics. Roche offers advanced biomarker testing solutions, neurodegenerative disease diagnostics, immunoassays, and molecular diagnostic platforms relevant to Parkinson’s disease research and early detection.
The company has a strong presence in neurological biomarker development through its Elecsys diagnostic portfolio and partnerships in neurodegenerative disease research. Roche generates billions in annual diagnostics revenue, with neurology and biomarker testing contributing significantly to its precision diagnostics business.
Recent developments include advancements in cerebrospinal fluid (CSF)-based biomarkers, AI-enabled neurological diagnostics, and collaborations focused on Parkinson’s and Alzheimer’s biomarker validation. Roche strategically focuses on precision medicine, early disease detection, and companion diagnostics.
Its key customers include hospitals, diagnostic laboratories, pharmaceutical companies, neuroscience research institutes, and academic institutions. Roche reported total revenues exceeding CHF 58 billion in 2025, with diagnostics remaining a major growth segment.
Bio-Rad Laboratories
Bio-Rad Laboratories is headquartered in Hercules, California, U.S. The company develops life science research technologies and diagnostic systems used in neurological biomarker discovery and protein analysis.
Bio-Rad provides PCR systems, immunoassay technologies, droplet digital PCR (ddPCR), and multiplex biomarker analysis platforms utilized in Parkinson’s disease biomarker research. The company plays an important role in supporting research institutions and pharmaceutical companies involved in neurodegenerative disease studies.
Recent innovations include expanded biomarker assay capabilities, digital PCR advancements, and collaborations supporting precision neurology research. Bio-Rad strategically focuses on life science innovation, high-sensitivity diagnostics, and translational medicine applications.
Its customers include biotech firms, pharmaceutical companies, academic research centers, and clinical laboratories. Bio-Rad generated approximately USD 2.7 billion in annual revenue in 2025.
Thermo Fisher Scientific
Thermo Fisher Scientific is headquartered in Waltham, Massachusetts, U.S. Thermo Fisher offers a broad portfolio of biomarker discovery solutions, mass spectrometry systems, sequencing technologies, antibodies, and proteomics platforms used in Parkinson’s disease research.
The company is a leading supplier of laboratory technologies supporting neurodegenerative biomarker identification and validation. Thermo Fisher’s neuroscience solutions are widely adopted across pharmaceutical R&D and academic neuroscience research.
Recent developments include AI-integrated proteomics workflows, advanced biomarker assay kits, and strategic investments in precision diagnostics and neurobiology research technologies. Thermo Fisher’s competitive advantage lies in its comprehensive end-to-end research ecosystem.
The company serves pharmaceutical manufacturers, biotechnology firms, hospitals, CROs, and academic institutions globally. Thermo Fisher reported annual revenues exceeding USD 44 billion in 2025.
Abbott Laboratories
Abbott Laboratories is headquartered in Abbott Park, Illinois, U.S. Abbott develops diagnostic assays, immunoassay analyzers, point-of-care testing systems, and neurological biomarker detection technologies.
The company’s diagnostics division is actively involved in biomarker research for neurodegenerative diseases, including Parkinson’s disease. Abbott’s Alinity and ARCHITECT diagnostic platforms are widely used for biomarker testing and laboratory diagnostics.
Recent innovations include high-sensitivity immunoassays, AI-assisted diagnostics, and partnerships focused on neurological disease detection. Abbott strategically emphasizes decentralized diagnostics, automation, and precision medicine.
Its customer base includes hospitals, clinical laboratories, diagnostic centers, and healthcare providers worldwide. Abbott reported revenues of approximately USD 42 billion in 2025.
Quanterix
Quanterix is headquartered in Billerica, Massachusetts, U.S. Quanterix specializes in ultra-sensitive digital biomarker analysis technologies for neurological disorders and precision medicine applications.
The company’s Simoa platform is widely recognized for detecting low-abundance neurological biomarkers associated with Parkinson’s disease and other neurodegenerative disorders. Quanterix has become a major innovator in blood-based biomarker testing.
Recent developments include partnerships with pharmaceutical companies for biomarker-driven clinical trials and expanded neurology assay offerings. The company focuses on ultra-sensitive diagnostics, neurodegeneration research, and liquid biopsy innovation.
Its customers include pharmaceutical firms, academic research institutes, biotechnology companies, and diagnostic laboratories. Quanterix reported annual revenues exceeding USD 150 million in recent financial disclosures.
Siemens Healthineers
Siemens Healthineers is headquartered in Erlangen, Germany. Siemens Healthineers offers imaging systems, laboratory diagnostics, AI-enabled healthcare technologies, and molecular diagnostic solutions supporting Parkinson’s disease diagnosis and biomarker analysis.
The company provides MRI systems, PET imaging technologies, and laboratory automation tools widely used in neurological disease diagnostics. Siemens strategically focuses on digital health integration and AI-assisted imaging analytics.
Recent innovations include AI-powered neuroimaging workflows, precision diagnostics partnerships, and advanced molecular imaging technologies. Siemens Healthineers serves hospitals, imaging centers, laboratories, and healthcare systems worldwide.
The company reported revenues exceeding EUR 22 billion in fiscal year 2025.
GE HealthCare
GE HealthCare is headquartered in Chicago, Illinois, U.S. GE HealthCare develops advanced imaging technologies, radiopharmaceuticals, and AI-driven healthcare solutions relevant to Parkinson’s disease diagnostics.
Its neurological imaging portfolio includes PET, MRI, and molecular imaging technologies used in biomarker-based neurodegenerative disease assessments. GE HealthCare has strengthened its AI-enabled imaging analytics and precision care capabilities.
Recent developments include collaborations in neuroimaging research, AI-powered imaging platforms, and digital diagnostics innovation. The company strategically focuses on precision healthcare and integrated diagnostic ecosystems.
GE HealthCare serves hospitals, imaging centers, healthcare providers, and neuroscience research institutions globally. The company generated over USD 20 billion in revenue in 2025.
PerkinElmer
PerkinElmer is headquartered in Waltham, Massachusetts, U.S. PerkinElmer provides biomarker detection systems, imaging technologies, immunoassays, and laboratory solutions supporting neurodegenerative disease research.
The company’s technologies are widely used in biomarker discovery, clinical diagnostics, and pharmaceutical research applications. PerkinElmer focuses on precision diagnostics and translational research.
Recent innovations include enhanced assay technologies, AI-supported laboratory automation, and neuroscience-focused biomarker research collaborations. Its customers include pharmaceutical companies, hospitals, research laboratories, and academic institutions.
PerkinElmer continues expanding its diagnostics and life sciences portfolio through acquisitions and strategic partnerships.
Sysmex Corporation
Sysmex Corporation is headquartered in Kobe, Japan. Sysmex develops clinical diagnostic instruments, laboratory automation systems, and biomarker testing technologies.
The company has expanded into neurological biomarker research through strategic collaborations and advanced assay development initiatives. Sysmex focuses on improving diagnostic efficiency, precision medicine, and laboratory automation.
Recent developments include partnerships for neurodegenerative biomarker validation and expansion of high-throughput diagnostic capabilities. Sysmex serves hospitals, diagnostic laboratories, and healthcare institutions worldwide.
The company reported revenues exceeding JPY 500 billion in 2025.
Biogen Inc.
Biogen Inc. is headquartered in Cambridge, Massachusetts, U.S. Biogen is a global biotechnology company specializing in neurological disease therapies and biomarker-driven neuroscience research.
The company actively invests in Parkinson’s disease biomarker discovery, neurodegenerative disease therapeutics, and precision medicine approaches. Biogen collaborates extensively with diagnostics companies and research organizations to develop biomarker-guided treatment strategies.
Recent developments include clinical-stage biomarker programs, AI-driven neuroscience research, and partnerships targeting neurodegenerative disease progression monitoring. Biogen strategically positions itself as a leader in neurological therapeutics and biomarker-enabled drug development.
Its customers and stakeholders include healthcare providers, pharmaceutical partners, neuroscience researchers, and patients globally. Biogen reported annual revenues exceeding USD 10 billion in 2025.
Explore Full Report : https://www.precedenceresearch.com/parkinsons-disease-biomarkers-market
Also Read Our Latest Post : Aluminum Market